Reference no: EM133293256

Identify the parties to the lawsuit by the role each has

Identify the jurisdiction in which the lawsuit is pending

Identify the damages that are being sought by the parties

Describe the Plaintiff's claim(s)

Describe the Defendant's defense(s)

Who do you think will prevail and why?

Elmiron is a bladder pain medication used to treat Interstitial Cystitis (IC), a chronic bladder condition. Recent research linked the drug to degenerative eye disease, leading injured victims to file a series of lawsuits against Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The lawsuits allege that Janssen Pharmaceuticals failed to warn users of the dangerous side effects of Elmiron, thereby knowingly putting consumers at risk of injury.

In 2019, Kaiser Permanente, Emory Eye Center, and Harvard conducted research and clinical studies that showed Elmiron usage could cause maculopathy, resulting in a loss of central vision. In line with their research, Kaiser Permanente studies found that 24% of 91 Elmiron users had pigment damage causing poor vision after fifteen years of using Elmiron.

They also discovered a 42% higher toxicity rate in patients that took 1500 mg or more of Elmiron. In addition, Emory Eye Center concluded that Elmiron caused significant eye degeneration and vision loss after seven years of usage, and Harvard research showed severe eye degeneration even in users that had stopped taking Elmiron.

The Elmiron (Pentosan Polysulfate Sodium) Products Liability litigation is currently pending, centralized in the United States District Court District of New Jersey.